Radical intervention in early rheumatoid arthritis. The case for enteric-coated sulphasalazine, methotrexate and combination regimens. WorkshopVAN DE PUTTE, Leo B. A; WEINBLATT, Michael E.British journal of rheumatology. 1995, Vol 34, issn 0263-7103, 116 p., SUP2Conference Proceedings

How and when should combination therapy be used ? The role of an anchor drugFARR, M; BACON, P. A.British journal of rheumatology. 1995, Vol 34, pp 100-103, issn 0263-7103, SUP2Conference Paper

The history of the use of sulphasalazine in rheumatologyAMOS, R. S.British journal of rheumatology. 1995, Vol 34, pp 2-6, issn 0263-7103, SUP2Conference Paper

Efficacy of methotrexate in rheumatoid arthritisWEINBLATT, M. E.British journal of rheumatology. 1995, Vol 34, pp 43-48, issn 0263-7103, SUP2Conference Paper

Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritisFURST, D. E.British journal of rheumatology. 1995, Vol 34, pp 20-25, issn 0263-7103, SUP2Conference Paper

The antirheumatic agents sulphasalazine and methotrexate share and anti-inflammatory mechanismCRONSTEIN, B. N.British journal of rheumatology. 1995, Vol 34, pp 30-32, issn 0263-7103, SUP2Conference Paper

Therapeutic approaches for early rheumatoid arthritis. How early ? How aggressive ?EMERY, P.British journal of rheumatology. 1995, Vol 34, pp 87-90, issn 0263-7103, SUP2Conference Paper

Short-term outcomes in recent-onset rheumatoid arthritisYOUNG, A.British journal of rheumatology. 1995, Vol 34, pp 79-86, issn 0263-7103, SUP2Conference Paper

Clinical trial design for evaluating combination therapiesPAULUS, H. E.British journal of rheumatology. 1995, Vol 34, pp 92-95, issn 0263-7103, SUP2Conference Paper

Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritisWILLIAMS, H. J.British journal of rheumatology. 1995, Vol 34, pp 96-99, issn 0263-7103, SUP2Conference Paper

Sulphasalazine : mechanism of action in rheumatoid arthritisSMEDEGARD, G; BJÖRK, J.British journal of rheumatology. 1995, Vol 34, pp 7-15, issn 0263-7103, SUP2Conference Paper

Clinical efficacy of sulphasalazine : a reviewCAPELL, H. A.British journal of rheumatology. 1995, Vol 34, pp 35-39, issn 0263-7103, SUP2Conference Paper

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid : which is the active moiety in rheumatoid arthritis ?BIRD, H. A.British journal of rheumatology. 1995, Vol 34, pp 16-19, issn 0263-7103, SUP2Conference Paper

Long-term outcomes in rheumatoid arthritisPINCUS, T.British journal of rheumatology. 1995, Vol 34, pp 59-73, issn 0263-7103, SUP2Conference Paper

Combination of sulphasalazine and methotrexate in the management of rheumatoid arthritis : view based on personal clinical experienceSHIROKY, J. B.British journal of rheumatology. 1995, Vol 34, pp 109-112, issn 0263-7103, SUP2Conference Paper

Possible mechanisms of action of methotrexate in patients with rheumatoid arthritisKREMER, J. M.British journal of rheumatology. 1995, Vol 34, pp 26-29, issn 0263-7103, SUP2Conference Paper

Joint erosions and patients with early rheumatoid arthritisVAN DER HEIJDE, D. M. F. M.British journal of rheumatology. 1995, Vol 34, pp 74-78, issn 0263-7103, SUP2Conference Paper

Female sex increases risk for rheumatoid arthritis only in individuals encoding low-risk HLA-DRB1 allelesDE VRIES, Niek; TAK, Paul P; TIJSSEN, Henk et al.Arthritis and rheumatism. 2003, Vol 48, Num 6, pp 1762-1763, issn 0004-3591, 2 p.Article

Role of Fcy receptors IIa, IIIa, and IIIb in susceptibility to rheumatoid arthritisRADSTAKE, Timothy R. D. J; PETIT, Elisabeth; PIERLOT, Cieline et al.Journal of rheumatology. 2003, Vol 30, Num 5, pp 926-933, issn 0315-162X, 8 p.Article

Adverse events in methotrexate-treated rheumatoid arthritis patientsSANDOVAL, D. M; ALARCON, G. S; MORGAN, S. L et al.British journal of rheumatology. 1995, Vol 34, pp 49-56, issn 0263-7103, SUP2Conference Paper

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritisDEN BROEDER, Alfons; VAN DE PUTTE, Leo B. A; KEMPENI, Joachim et al.Journal of rheumatology. 2002, Vol 29, Num 11, pp 2288-2298, issn 0315-162X, 11 p.Article

Genetic anticipation in rheumatoid arthritis in EuropeRADSTAKE, Timothy R. D. J; BARRERA, Pilar; ALBERS, Mieke J. C et al.Journal of rheumatology. 2001, Vol 28, Num 5, pp 962-967, issn 0315-162XConference Paper

Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritisBARRERA, Pilar; BLOM, Arjen; VAN LENT, Peter L. E. M et al.Arthritis and rheumatism. 2000, Vol 43, Num 9, pp 1951-1959, issn 0004-3591Article

Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritisVAN RIEL, P. L. C. M; VAN GESTEL, A. M; VAN DE PUTTE, L. B. A et al.British journal of rheumatology. 1995, Vol 34, pp 40-42, issn 0263-7103, SUP2Conference Paper

The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor α expression in macrophages by inducing apoptosisRODENBURG, Richard J. T; GANGA, Anuradha; VAN LENT, Peter L. E. M et al.Arthritis and rheumatism. 2000, Vol 43, Num 9, pp 1941-1950, issn 0004-3591Article